cyclic IL-17RB peptide

The cyclic IL-17RB peptide is a research-stage therapeutic biologic designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). Derived from the IL-17RB receptor sequence (specifically amino acids 403-416), this peptide was engineered into a disulfide-bonded cyclic form to enhance metabolic stability and cellular uptake compared to its linear precursor, TAT-IL17RB403–416. Its primary mechanism of action involves disrupting the protein-protein interaction between IL-17RB and mixed-lineage kinase 4 (MLK4), which is a critical driver of oncogenic signaling and metastasis in the IL-17B/IL-17RB axis. Specifically, the peptide targets the interaction mediated by cysteine 408 of IL-17RB and arginine 216 of the MLK4 kinase domain. Developed by researchers at Academia Sinica, the peptide has demonstrated the ability to inhibit tumor growth and metastasis in preclinical orthotopic mouse models of pancreatic cancer.

Other names

cyclic IL-17RB403–416disulfide-bonded cyclic IL-17RB peptide